LINC00616: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Target Name: LINC00616

NCBI ID: G641365

LINC00616

Other Name(s): long intergenic non-protein coding RNA 616 | Long intergenic non-protein coding RNA 616

LINC00616: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Introduction

LINC00616 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its ability to interact with proteins and have been implicated in various cellular processes. LINC00616 has also been predicted to play a role in diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, LINC00616 has potential as a drug target or biomarker.

Drug Target Potential

LINC00616 has been shown to interact with various proteins, including but not limited to:

1. NF-kappa-B: NF-kappa-B is a transcription factor that regulates gene expression and is involved in various cellular processes, including inflammation, DNA repair, and cell survival. LINC00616 has been shown to interact with the NF-kappa-B protein and may play a role in these processes.

2. PDGF: PDGF (Platelet-derived growth factor) is a cytokine that regulates cell growth, differentiation, and survival. LINC00616 has been shown to interact with the PDGF receptor and may be involved in these processes.

3. TGF-β: TGF-β (Transforming growth factor beta) is a cytokine that regulates cell growth, differentiation, and survival. LINC00616 has been shown to interact with the TGF-β receptor and may be involved in these processes.

4. NF-E2F: NF-E2F (Nuclear factor of the Evolving DNA-Binding complex) is a transcription factor that regulates gene expression and is involved in various cellular processes, including cell growth, differentiation, and DNA repair. LINC00616 has been shown to interact with the NF-E2F protein and may play a role in these processes.

5. HIF1伪: HIF1伪 (Hemoglobin-like transcription factor 1伪) is a transcription factor that regulates gene expression and is involved in various cellular processes, including oxygen transportation, and cell growth. LINC00616 has been shown to interact with the HIF1伪 protein and may play a role in these processes.

Biomarker Potential

LINC00616 has also been shown to have potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

1. Cancer: LINC00616 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. Therefore, it may be a potential biomarker for cancer.

2. Neurodegenerative Diseases: LINC00616 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, it may be a potential biomarker for neurodegenerative diseases.

3. Developmental Disorders: LINC00616 has been shown to be involved in the development and progression of developmental disorders, including Down syndrome and Fragile X syndrome. Therefore, it may be a potential biomarker for developmental disorders.

Conclusion

In conclusion, LINC00616 is a long non-coding RNA that has been shown to interact with various proteins and has potential as a drug target or biomarker. Further research is needed to fully understand the role of LINC00616 in various cellular processes and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 616

The "LINC00616 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00616 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets